


Division of Research Florida Atlantic University

CLINICAL RESEARCH UNIT INVESTIGATOR MANUAL VERSION 6.0

December 19, 2023



### Contents

Welcome	2
Procedures for Clinical Research Unit Use	3
Appendix A: Request for Clinical Research Unit Consultation Meeting	5
Appendix B: Application for Clinical Research Unit Services	6
Appendix C: Sample Protocol Initiation/In-service Meeting Agenda	8
Appendix D: Appointment Scheduling Form	10
Appendix E: Study Visit Orders	12
Appendix F: Request for Change in Research Services	12

#### Welcome

#### Welcome Researchers!

Thank you for choosing to carry out your research project at the FAU Division of Research Clinical Research Unit (CRU). The mission of the CRU is to provide dedicated research clinical facilities and experts to foster partnerships between academic leadership and medical investigators. The Clinical Research Unit can provide the tools, training, and guidance to properly conduct clinical research. We have a dedicated staff of professionals who are skilled in several aspects of clinical research, including study startup, project coordination, and regulatory oversight.

Enclosed you will find the steps needed to engage CRU services, the application steps and necessary forms, and information regarding investigator responsibilities. Please read the information provided in this packet carefully. If you have any questions, please contact the CRU staff. We look forward to working with you on your project!

Judyta Kociolek, MSN, RN Director of Clinical Research Unit (CRU) Operations 561-297-4963 jkociolek2017@health.fau.edu

Clinical Research Unit (CRU)
Division of Research
Florida Atlantic University
777 Glades Road, ME-104, Suite 104
Boca Raton, FL 33431
CRUDOR@health.fau.edu

#### **Procedures for Clinical Research Unit Use**

#### 1. Pre-Submission Consultation

All researchers who wish to use the Clinical Research Unit (CRU) space, personnel, or equipment for conducting studies with human participants must submit the Request for Clinical Research Unit Consultation Meeting form (Appendix A). Investigators should submit the form as early as possible, preferably when the project is being prepared for submission to the funding agency, but no later than 30 days before submission to the Institutional Review Board (IRB). Investigators are encouraged to engage with the CRU at the time of study development to minimize delays in study approval and execution. Along with the form, investigators should submit the current protocol, schedule of events, consent form, lab manual, drug or device brochure, and any other documents that would be relevant or helpful to CRU staff. Once the application is received, CRU staff will review the documents to ensure that the unit can effectively meet the needs of the study and will set up a meeting with the investigator's team to discuss the project's needs and how the CRU can meet them. After the meeting, the CRU will confirm the feasibility of the study and prepare a letter of agreement for CRU services, which will include – for funded studies - costs for the use of CRU services. This document will be forwarded to the investigator for review, approval, and signature.

The investigator will return a copy of the signed agreement via email to <a href="mailto:CRUDOR@health.fau.edu">CRUDOR@health.fau.edu</a>. The approval process is expected to take less than 30 days.

Due to the nature of the CRU as a core unit, the signed agreement will serve as documentation for the IRB and IBC submissions of the CRU as performance site. This document will avoid listing each individual personnel from the CRU in the compliance applications if allowed. All CRU standard procedures and personnel training have been approved by the compliance committees and listing the CRU as a core will eliminate - on a case-by-case basis- repeated submission of SOPs and certifications from the CRU.

#### 2. Principal Investigator Eligibility

The CRU supports all levels of clinical research investigators including those in training working under the oversight of an FAU eligible Principal Investigator (PI).

Following FAU policy 10.2.8, individuals employed by Florida Atlantic University that hold one of the following positions may serve as PI and Co-Principal Investigator (Co-PI).

#### Principal Investigator:

- Faculty Tenure-Track (Full, Associate and Assistant Professors)
- Research Faculty NON-Tenure-Track (Full, Associate and Assistant Professors)
- Clinical Research Faculty NON-Tenure-Track (Full, Associate and Assistant Professors)
- Executive Directors, Directors, Associate and Assistant Directors within Pillars/Institutes and other FAU units
- Instructors holding a regular, full-time (1FTE) appointment at FAU
- Librarians holding faculty status equivalent to or greater than Assistant Professor
- Vice Presidents, Senior/Executive Associate VP, Associate VP and Assistant VP serving in these positions at FAU in any of the service areas (Research, Student Affairs, etc.)
- Principals, Assistant Principals, Directors (Associate and Assistant) and Professors (Associate and Assistant) for A.D. Henderson University School and FAU High School.
- Senior Research Fellows senior position given to a postdoctoral fellow.

#### Co-Principal Investigator/Co-Investigator Positions List:

- Adjunct Faculty
- Affiliate Faculty
- Post-Doctoral Fellows
- Visiting Faculty

**External users** who hold a formal appointment of *Clinical Research Assistant Professor*, *Clinical Research Associate Professor* or *Clinical Research Professor* in one of the Pillar Institutes, a college or as a cross-appointment between a Pillar and a college can serve as PI in projects using the CRU for clinical research.

Other external investigators (i.e.: clinical affiliates) MUST identify and collaborate with eligible FAU PI to be able to conduct their research at FAU.

For more information, please visit the website below, and click Policy 10.2.8 Principal Investigator Eligibility Policy:

https://www.fau.edu/research-admin/sponsored-programs/policies/

#### 3. Application for Clinical Research Unit Services

When the investigator receives notification that the project is funded or, for non-funded projects, when the investigator is ready to submit to the compliance committees, the Application for Clinical Research Unit Services (Appendix B) must be completed and submitted via email to <a href="mailto:CRUDOR@health.fau.edu">CRUDOR@health.fau.edu</a>. This application is the official request to use CRU services and may be submitted concurrently with IRB and other committee submissions (Institutional Biosafety Committee, Imaging Committee, other committees as applicable). The CRU must be listed on the IRB application as a performance site. Applications are reviewed on a rolling basis as soon as all the required documents are received.

Once compliance approvals are obtained, please communicate with the CRU to order supplies needed for the study. If specialized supplies are needed, longer times should be planned to order and receive supplies in the period between compliance approvals and study in-service meeting.

#### Required Training

CRU staff members have completed required CITI, Environmental Health & Safety, and Institutional Biosafety Committee training, as well as other training relevant to their job functions. Investigators wishing to use the CRU for their research studies and their research staff also need to complete research-specific training, as applicable. Training requirements are as follows:

- CRU Standard Operating Procedures
- HIPPA Privacy Essentials Course it has been replaced with CITI Information Privacy & Security (IPS) training
- CITI training required by Research Integrity: https://www.fau.edu/research-admin/research-integrity/responsible-conduct-of-research/
- Environmental Health & Safety training http://www.fau.edu/ehs/training/
- Institutional Biosafety Committee training
   <a href="https://www.fau.edu/research-admin/research-integrity/institutional-biosafety-committee/ibc-training-requirements/">https://www.fau.edu/research-admin/research-integrity/institutional-biosafety-committee/ibc-training-requirements/</a>

Additional training may be required based on the nature of the study being conducted. CRU staff FAU/CRU – Investigator Manual Version 5 – 23/June/2023 Page 5 of 28

have completed CITI, IATA, and Environmental Health & Safety training; documentation of training is available upon request.

#### 4. Protocol Initiation/In-service Meeting and Study Initiation in the CRU

The investigator's study staff must draft and submit study procedure orders and data collection flowsheets to the CRU for review and approval; CRU staff can assist with this process if needed. The investigator will schedule a protocol initiation/in-service meeting once the following have been completed:

- All compliance approvals have been received
- Training for all staff who will be working on the study has been completed
- The investigator's team is ready to begin the study in the CRU

The in-service should occur approximately four (4) weeks before the first participant is scheduled. A sample agenda for this meeting can be found in Appendix C. At this meeting, study procedures to be completed on the CRU, visit scheduling procedures, study order sheets, data collection, and other topics important for the study to be carried out in the CRU will be discussed. Attendees at this meeting should include the study investigators, study staff who will be accessing the CRU during the conduct of the study, and CRU staff members who will be working on the study.

Once the investigator and all staff who will be involved in the study have completed all start-up requirements, the investigator will receive notification that the study may commence in the CRU. The checklist below may be used to assist with confirming that all requirements have been completed.

Complete	N/A	
		Institutional Review Board approval: letter submitted to CRU
		Institutional Biosafety Committee approval, if applicable: letter submitted to CRU
		Imaging Committee approval, if applicable: letter submitted to CRU. Imaging Committee will not approve the study without all staff involved in imaging completing training on the applicable imaging modality(-ies).
		CV and medical license of principal investigator and investigator providing medical oversight: submitted to CRU, if applicable
		CITI training required by Research Integrity completed by all study staff who will be accessing the unit. Clearance letter for all staff members submitted to CRU.
		Training required by FAU Environmental Health & Safety completed by all study staff who will be accessing the unit. Clearance letter for all staff members submitted to CRU.
		Training required by FAU Institutional Biosafety Committee. Clearance letter for all staff members submitted to CRU.
		CRU Standard Operating Procedure training
		Other training, as applicable
		Research procedure orders in place
		Data collection forms in place
		Protocol Initiation/In-service Meeting
		Letter approving start of study in CRU received

If there are study-provided lab kits, supplies, or equipment to be used for the study, these items should be discussed at the initiation/in-service meeting. Any equipment brought into the CRU must be tested for electrical safety and calibrated, if applicable, by biomedical engineering.

#### 5. ClinicalTrails.gov Requirement

The PIs are required by law to submit registration for certain clinical trials of drug products (including biological products) and device products to ClinicalTrails.gov, in accordance with the Final Rule for Clinical Trials Registration and Results Information Submission (42CFR Part 11) and Section 801 of the Food and Drug Administration Amendments Act (FDAAA 801). Please, see the Final Rule Information page by clinking the link below:

https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission

In accordance with 42 CFR Part 11, there must be one responsible party for the purposes of submitting information about applicable clinical trial. The sponsor of an applicable clinical trial is considered to be a responsible party unless the sponsor designates a qualifies PI as the responsible party. The responsible party must register an applicable clinical trial no later than 21 calendar days after enrolling the first human subject.

In addition to registering clinical trials, the sponsor or the PI is responsible for providing timely updates, submitting summary results, and making information publicly available in order to fulfill a number of purposes and stay compliant with multiple laws.

For more information, please visit the website below:

https://clinicaltrials.gov/ct2/manage-recs/background

#### 6. Study Conduct

Appointments may be scheduled in the CRU during the hours of operation, Monday-Friday 8:00AM – 5:00PM. All study appointments will be coordinated by CRU staff and should be scheduled before 4:00PM. Anyone needing study appointments after 4:00PM must receive written authorization from the CRU Director or CRU Assistant Director.

Appointments are requested using the Appointment Scheduling Form (Appendix D), which should be sent via email to <a href="CRUDOR@health.fau.edu">CRUDOR@health.fau.edu</a>. Research procedure orders (Appendix E) signed by the investigator must be received at least 72 hours prior to the appointment. Once the appointment time is approved, a calendar invite will be sent to the investigator, study staff, physician providing medical oversight (if applicable), and CRU staff. When required, it is the investigator's responsibility to ensure that appointments are scheduled when a physician is available for medical oversight. Appointments should be scheduled as soon as possible before the visit, but at least 72 hours prior; CRU staff will do their best to accommodate last-minute appointment requests, but accommodation cannot be guaranteed.

Unless the participant is consented for the study in the CRU, study staff must bring copies of the signed consent and HIPAA forms (if applicable) with them to the participant's first visit. These documents will be filed in the CRU's study files. When participants are reconsented during the course of the study, those documents should also be submitted to the CRU for filing.

When the investigator receives a continuing renewal letter (annually) from the IRB, a copy of the letter must be provided to the CRU as proof of ongoing study approval. The CRU must also be notified when the investigator closes the study.

It is the investigator's responsibility to report adverse events, serious adverse events, protocol deviations, and other issues that affect the rights or safety of study participants to the funding agency and/or IRB within the proscribed time frames.

Investigators must notify the CRU Director or CRU Assistant Director in writing as soon as possible when a study monitor, sponsor, or regulatory agency has requested to visit the CRU.

#### 7. Changes in Research Services

Any changes to the research conducted in the CRU must be submitted on a Request for Change in Research Services form (Appendix F) and submitted to the CRU for review and approval before changes in research procedures can be made. This approval is over and contingent to any approvals needed from the IRB or ancillary committees.

Appendix A:	: Request for Clinic	cal Research Unit	Consult Meetina



# Form 1 - Request for Clinical Research Unit Consult Meeting

Please submit this form and applicable documents to <u>CRUDOR@health.fau.edu</u>.

Today's Date (DD/MMM/YYYY): / / /
Principal Investigator Information
Name: Department/College:
Phone: Email:
Other Contact: Title:
Phone: Email:
Study Information
Project Title:
IRB #: Sponsor/Other #:
ICD-10 Diagnosis Codes/Research Indication:
Brief Project Description:
Funding Source
Funding Source: NIH/Federal Foundation Private
☐ Industry ☐ Department ☐ State/Local
☐ Not Funded ☐ Other
Sponsor Name:
Estimated # Participants:
Planned Start Date (DD/MMM/YYYY): / /
Planned End Date (DD/MMM/YYYY): / / /
Description of CRU Services Needed
Are there any special days/times that your visits need to be scheduled?
□ No □ Yes Explain:
Will you be providing any study-specific supplies, forms, or equipment (lab kits, machines, flow sheets, orders, etc.)?
□ No □ Yes Explain:
Is there any other information about your project that you feel it is important for the CRU to consider?
□ No □ Yes Explain:

#### Are the following documents attached? Protocol/Grant Version: ☐ Yes ☐ No □ N/A Application ☐ Yes ☐ No ☐ N/A Informed Consent Version: Lab Manual Yes ☐ No ☐ N/A Version: Schedule of Events Version: Yes ☐ No ☐ N/A For Clinical Trials: CV/Biosketch and Yes Version: ☐ No □ N/A Medical License of **Investigator Providing** Medical Oversight

Additional Document(s)

Appendix B: Application for Clinical Research Unit Services



#### Form 2 - Application for Clinical Research Unit Services

Please submit this application and applicable documents to CRUDOR@health.fau.edu. **Principal Investigator Information** Name: Department/College: Academic Rank: Specialty: Phone: Email: Other Contact: Title: Phone: Email: **Medical Oversight Physician Information** (if applicable) Name: Department/College: Rank: Specialty: Email: Phone: Co-/Sub-Investigators Name: Department/College: Name: Department/College: Name: Department/College: Name: Department/College: Department/College: Name: **Study Information Project Title:** IRB#: Sponsor/Grant/Other #: IRB of Record: IRB Submission Date (DD/MMM/YYYY): Approved Pending If Approved, IRB Expiration Date (DD/MMM/YYYY): Funding Source: NIH/Federal Foundation Private Department State/Local Industry Not Funded ☐ Other Investigational: IDE ☐ BLA □ NDA ANDA □ N/A Number(s): Name: Study Phase: □ I-II III-IV  $\square$  IV N/A

Pilot

lnv	estigator-Initiated?	Yes		
Participan	t Information			
# F	Participants:	Planned Start Date	(DD/MMM/YYYY): /	/
Та	rget Population:			
ICI	D-10 Diagnosis Code(s):			□ N/A
Pa	rticipant Age Range:	Planned End Date (	DD/MMM/YYYY): /	1
#\	/isits/Participant:	Estimated Length of	f Visits: (15 min increment	s):
Ме	edical risks (cardiac, vascula	ar, pulmonary, etc.)?	☐ Yes	☐ No
Ве	havioral risks (agitation, ag	gression, psychosis, paranoia	a, etc.)?	☐ No
Co	gnitive risks (memory, atten	tion, confusion, etc.)?	☐ Yes	☐ No
Fa	Il precautions?		☐ Yes	☐ No
Se	izure precautions?		☐ Yes	☐ No
Inf	ection control requirements	s?	☐ Yes	☐ No
Nu	rsing assistance required?		☐ Yes	☐ No
		were answered "yes", plea	ase explain how risks to r	esearch
	rticipants will be mitigated ata Safety Committee bee		es 🗆 No	
i ias a D	ata Safety Committee bee	il established!	es 🗀 NO	
CR	U Services Requested (s	elect all that apply)		
	Phlebotomy†	☐ Specimen Storage†	☐ Informed Consent	☐ Vital Signs
	Single Draw	-80 freezer	☐ Physical Exam	☐ Weight
	☐ Multiple Draws	20 freezer	☐ Cognitive Testing	☐ Height
	Urine Sample†	☐ Refrigerator	☐ Infusion Pump Use	☐ ECG
	Oral/Buccal Swab†	☐ Urinalysis†	☐ Fecal Sample†	☐ Exam Room
	Specimen Processing†	☐ Specimen Shipment†	ECG Machine Use	Ultrasound
	Monitoring/Observation	Exam Room Use	Study Coordinator	☐ Nursing
	Pharmacy Services	☐ Infusion Bay Use	☐ DXA Scans‡	☐ Regulatory
	Glucose Finger Stick†	☐ Urine HCG Testing	☐ Anthropometrics	☐ Data Entry
	Administer Medication	☐ Functional Testing	☐ Gait Lab Use	□ ост
	Auditory Testing	☐ Visual Testing	☐ Spirometry	Audiometry
	Ankle-brachial Index	☐ Body Composition	☐ Pulse Oximetry	☐ Hand Grip
	Waist Circumference	Strength Testing	☐ Hand Dexterity	Screening
	Balance Assessment	☐ Gait Testing	☐ Interview Room	☐ Nasal Swab†
	Other:			

<sup>†</sup> Protocols involving collection of samples must receive approval from the FAU Institutional Biosafety Committee. ‡ Protocols involving imaging must receive approval from the FAU Human & Animal Imaging Committee.

Supplies to Be Provided by Investigator				
Supplies to Be Provided by CRU				
Financial Information: Billing  Contact: Tag #:	1	Phone:	-	
Award #:	Award	d Amount: \$		
Dates of Grant Support / / / / / / (DD/MMM/YYYY):	to	1 1		
Voucher Support Requested?				
Are any procedures billable to insurance?	_	′es ☐ No		
Required Attachments (mandatory in order		′es ∐ No	uso the unit):	
Final Protocol/Grant Application	∏ Yes	— No	Pending	□ N/A
Schedule of Events	☐ Yes	☐ No	☐ Pending	☐ N/A
IRB-Approved Informed Consent	□ □ Yes	☐ No	☐ Pending	□ N/A
IRB Determination Letter	☐ ☐ Yes	☐ No	☐ Pending	Ш
IBC Approval Letter	 ☐ Yes	 □ No	☐ Pending	□ N/A
Imaging Committee Approval Letter	Yes	No	Pending	N/A
Final Lab Manual	Yes	☐ No	☐ Pending	$\square_{N/A}$
Final Pharmacy Manual	Yes	☐ No	☐ Pending	□ <sub>N/A</sub>
Visit Flow Sheets	Yes	□ No	☐ Pending	□ N/A
Study Visit Orders	□Yes	$\square$ No	Pending	□ <sub>N/A</sub>

## Additional Document(s)

Are you planning on collecting any data and/or samples off campus?	☐ Y	es	□ N	lo	
If yes, do you have study personnel to collect your data and/or samples?	Y	′es		No	N/A
If yes, do you have an FAU designated vehicle to travel off campus and transport your specimens?		Yes		No	N/A
If you need the CRU to process your samples, do you have a plan to deliver/ship those samples to the CRU?		Yes		No	N/A

Application Completed & Submitted By:

#### Responsibility for Scientific Conduct:

I attest the information provided in this application is current and accurate. In addition, I confirm that:

- I will adhere to the FAU Division of Research Policies and Clinical Research Unit Standard Operating Procedures.
- I will ensure that all personnel from my staff who utilize the Clinical Research Unit complete the required training.
- I will ensure that the study is conducted as approved by the IRB.
- I will provide the Clinical Research Unit with amendments, continuing approvals, and other reports and updated documents in a timely manner.
- I will report adverse events to the Clinical Research Unit and/or the IRB within the required time frames.

Principal Investigator Name (PRINT):	
Principal Investigator Signature:	
Date:	<del></del>
<ul> <li>I will accept responsibility for the sa</li> <li>I will ensure that all subjects meet a</li> </ul>	ibility for medical oversight for this protocol. afety of the human subjects enrolled under this protocol.
Medical Oversight Physician Signature:	
Date:	

	Appendix C: Sample Protocol Init	iation/In-service Meeting Agen	da
LI/CRII — Investigator	Manual Version 5 - 23/June/2023	Page 10 of 28	



# Initiation/In-service Meeting Agenda [Protocol Name] [Principal Investigator] [Date]

Please bring the following documents to the initiation/in-service meeting:

- IRB approval letter
- Final protocol/grant application, consent form, and other study-related documents
- Copies of study flowsheets/data collection forms & study visit orders
- Lab processing instructions/lab manual
- Other documents needed for CRU staff to complete study tasks

#### The meeting should cover the following items:

- 1. Project Title
- 2. Staff Introductions
  - a. Principal Investigator
  - b. Co-/Sub-Investigator(s)
  - c. Other study staff with whom CRU staff may be interacting
- 3. Project Overview
  - a. Brief description of the study
  - b. Aims/goals of the study
  - c. Anticipated start date
  - d. Length of study participation
  - e. Number of planned participants
  - f. Information about the study intervention (drug, device, procedure, etc.)
- 4. CRU-Specific Study Details
  - a. Number, frequency, & length of study visits
  - Visit scheduling procedures, including specific timing and scheduling form review
  - c. Coordinator and/or nursing tasks
  - d. Study participant number/ID assignment
  - e. Consent procedures, if applicable
  - f. Data collection procedures, including forms
  - g. Study orders
  - h. Any special training or equipment needed
  - i. Expected adverse events and reporting procedures
  - j. Procedures to contact investigator and/or other study staff in case of emergency & medical coverage
- 5. Lab Instructions
  - a. Type, number of collection tubes
  - b. Supplies provided by study or need to be purchased
  - c. Sample collection conditions (ambient, refrigerated)
  - d. Centrifugation instructions (temperature, speed, time)
  - e. Sample storage conditions (ambient, refrigerated, -20, -80)
  - f. Number of aliquots, timing, labeling instructions
  - g. Any other study-specific processing procedures
- 6. Other considerations

Appendix D: Appointment Scheduling Form



**Study Information** 

# FLORIDA ATLANTIC UNIVERSITY

Use one form per participant. Please submit this form to <a href="mailto:CRUDOR@health.fau.edu">CRUDOR@health.fau.edu</a>.

IRB#					
Requested By:					
Request Date:					
Investigator Informat	ion				
Name:					
Phone:	(	)	-		
Email:					
Study Staff Information	on				
Name:					
Phone:	(	)	-		
Email:					
24/7 Contact for Medi	cal E	merg	encies		
Name:					
Phone:	(	)	-		
Signed study consents/reconsents MUST be provided to CRU staff before or at the time of first visit for any study visits using CRU staff.					
Participant Informa					
Participant ID:					
Legal Name (Last, First, MI):					
Date of Birth					
(DD/MMM/YYYY):		/	/		
Phone Number:					
E mail:					
Visit Information					
`	1 visit,	use a	dditional	spaces on reverse side of this form)	
Study Visit ID:					
Visit Date (DD/MMM/YYYY):		/	/		

Visit Type:	☐ New ☐ Follow-Op ☐ Philebotomy ☐ Sample Drop-Oil
Arrival Time (HH:MM)	1
Anticipated Visit Length:	hours minutes (round to next 15-minute increment)
Staff Requirements:	
Space Requirements:	
Additional Comments:	
Visit Information	
Study Visit ID:	
Visit Date (DD/MMM/YYYY):	
Visit Type:	☐ New ☐ Follow-Up ☐ Phlebotomy ☐ Sample Drop-Off
Arrival Time (HH:MM)	:
Anticipated Visit Length:	hours minutes (round to next 15-minute increment)
Staff Requirements:	
Space Requirements:	
Additional Comments:	
Visit Information	
Study Visit ID:	
Visit Date (DD/MMM/YYYY):	
Visit Type:	☐ New ☐ Follow-Up ☐ Phlebotomy ☐ Sample Drop-Off
Arrival Time (HH:MM)	
Anticipated Visit Length:	hours minutes (round to next 15-minute increment)
Staff Requirements:	
Space Requirements:	

Additional Comments:	
Visit Information	
Study Visit ID:	
Visit Date (DD/MMM/YYYY):	
Visit Type:	☐ New ☐ Follow-Up ☐ Phlebotomy ☐ Sample Drop-Off
Arrival Time (HH:MM)	
Anticipated Visit Length:	hours minutes (round to next 15-minute increment)
Staff Requirements:	
Space Requirements:	
Additional Comments:	

**Appendix E: Study Visit Orders** 



# Form 4 - Clinical Research

CRUDOR@health.fau.edu	Participant ID:
Protocol #:	Participant Name:
Allergies	Date of Birth (DD/MMM/YYYY): / / /
Latex Yes No Food Yes No	Medications/Drugs  Yes  No  Medication Name Type of
Peanuts	Reaction
Eggs L	
Other (specify)	
	Orders ocedures requested for this order and include as many # tubes, butterfly, processing, specific test from cognitive battery,
PI/Designee Signature:	

Study Visit ID:

Appendix F: Request for Change in Research Services



## Form 5. - Request for Change in Research Services

#### Please submit this form and applicable documents to <a href="CRUDOR@health.fau.edu">CRUDOR@health.fau.edu</a>.

Today's Date (DD/MMM/YYYY): / / /	
Principal Investigator Name: Research Team Contact: Name: IRB #:	
Project Title:	
IRB Submission Date (DD/MMM/YYYY): / / / Approved Pending	
Changes to the Research	
Change in Number of Participants 🔲 Yes 🔲 No	
Change in Number of Visits	
Change in Study Activities	
Protocol Yes No	
Informed Consent	
Lab Manual	
Pharmacy Manual	
Additional Documents	
New Documents	
Additional Information/Comments:	
Are the following documents attached?	
Submit tracked changes version of each document or summary of changes, if available.	
Revised Protocol/Amendment	
Revised Informed Consent	
IRB Approval Letter	
Revised Lab Manual	
Other Revised/New Document(s)	
PI/Designee Signature:	
)ate·	_